Tejas Patil

Has grant

Assistant Professor

University of Colorado School of Medicine

United States

Research Interests

Explore related searches

Professors in United States Professors in Cancer Biology Cancer Biology professors in United States

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

About

Tejas Patil is an Assistant Professor at the University of Colorado School of Medicine in the United States. His research focuses on thoracic oncology, particularly in the development and evaluation of innovative treatment strategies for lung cancer, including the use of tyrosine kinase inhibitors and local therapy for oncogene-addicted non-small cell lung cancer. He has contributed significantly to the understanding of treatment responses in various metastatic conditions through articles exploring the efficacy of targeted therapies and deep-learning frameworks.

Recent Grants

Grant: Close

Use of spatial multiomics to characterize receptor tyrosine kinase adaptations of drug-tolerant persister cells in non-small cell lung cancer treated with tyrosine kinase inhibitors

Open Date: 2023-04-01

Close Date: 2025-04-01

Grant: Close

Characterizing MET receptor tyrosine kinase adaptations of drug-tolerant persister cells in non-small cell lung cancer treated with tyrosine kinase inhibitors

Open Date: 2023-04-01

Close Date: 2024-04-01

Grant: Close

Programmed death ligand 1 (PD-L1) expression as a biomarker for tyrosine kinase inhibitor (TKI) efficacy among patients with ALK-rearranged NSCLC

Open Date: 2022-06-01

Close Date: 2023-06-01

Grant: Close

MET and EGFR as biomarkers for amivantamab in overcoming RET TKI resistance

Open Date: 2022-04-01

Close Date: 2024-04-01

Grant: Close

Personalized medicine models and linked electronic database to assess racial and socioeconomic disparities among patients with lung cancer in Colorado

Open Date: 2020-07-01

Close Date: 2021-06-01

Articles (19)

Year:

2025

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2022

Year:

2022

Year:

2022

Year:

2021

Year:

2021

Year:

2021

Year:

2020

Year:

2020

Collaborators (3)

David Gerber

Professor of Internal Medicine (Hematology-Oncology) and Clinical Sciences

University of Texas Southwestern Medical Center

UNITED STATES

View details

Sanju Sinha

Assistant Professor

Sanford Burnham Prebys Medical Discovery Institute

UNITED STATES

View details

Raphael Nemenoff

Professor

University of Colorado Anschutz Medical Campus

UNITED STATES

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Tejas Patil

Research Interests

Explore related searches

Contact this professor

About

Recent Grants

Articles (19)

Development, Review, and Activation of Thoracic Oncology Investigator-Initiated Trials

Tyrosine Kinase Inhibitors With and Without Up-Front Stereotactic Radiosurgery for Brain Metastases From EGFR and ALK Oncogene–Driven Non–Small Cell Lung Cancer (TURBO-NSCLC)

Neoadjuvant Osimertinib for the Treatment of Stage I-IIIA Epidermal Growth Factor Receptor–Mutated Non–Small Cell Lung Cancer: A Phase II Multicenter Study

A deep-learning framework to predict cancer treatment response from histopathology images through imputed transcriptomics

The Role of Local Therapy for Oligo-Progressive Disease in Oncogene-Addicted Non-Small-Cell Lung Cancer

The Efficacy and Safety of Treating Acquired MET Resistance Through Combinations of Parent and MET Tyrosine Kinase Inhibitors in Patients With Metastatic Oncogene-Driven NSCLC

Clinical and Radiographic Benefit of a Patient With Metastatic Non-Small Cell Lung Cancer Harboring an EGFR::ERBB4 Fusion Through Use of EGFR Tyrosine Kinase Inhibitors

Exceptional response to lorlatinib and cabozantinib in ROS1-rearranged NSCLC with acquired F2004V and L2086F resistance

MET alterations in advanced non-small cell lung cancer

Larotrectinib efficacy and safety in adult patients with tropomyosin receptor kinase fusion sarcomas.

Long-Term Efficacy and Safety of Entrectinib in<i> ROS1</i> Fusion-Positive NSCLC

Adjuvant Osimertinib in EGFR-Mutant Early-Stage NSCLC: Does HRQoL Influence Decisions?

Case Report: Significant Clinical Benefit From Pemetrexed-Based Therapy in ROS1- and ALK-rearranged Lung Cancer With Adenosquamous Histology

Central Nervous System Response to Selpercartinib in Patient With RET-rearranged Non-small Cell Lung Cancer After Developing Leptomeningeal Disease on Pralsetinib

Evolution of MET and NRAS gene amplification as acquired resistance mechanisms in EGFR mutant NSCLC

Acquired Resistance to KRAS G12C Inhibition in Cancer.

A tyrosine kinase inhibitor-induced interferon response positively associates with clinical response in EGFR-mutant lung cancer

Duration of Targeted Therapy in Patients With Advanced Non–small-cell Lung Cancer Identified by Circulating Tumor DNA Analysis

Clinicopathologic Characteristics, Treatment Outcomes, and Acquired Resistance Patterns of Atypical EGFR Mutations and HER2 Alterations in Stage IV Non–Small-Cell Lung Cancer

Collaborators (3)

David Gerber

Sanju Sinha

Raphael Nemenoff

Make your next move.